Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
ESMO 2022: Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients | Semantic Scholar
Dose-Dense Adjuvant Chemotherapy “Optimal” for High-Risk Early Breast Cancer - Cancer Therapy Advisor
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis - Xiu - 2022 -
Survival benefit of pure dose-dense chemotherapy in breast cancer: a meta-analysis of randomized controlled trials | World Journal of Surgical Oncology | Full Text
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Comparisons of survival outcomes between the dose-dense group and the... | Download Scientific Diagram
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial | Journal of Clinical Oncology
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Trial design of AGO trial, intense dose-dense epirubicin, paclitaxel,... | Download Scientific Diagram
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - ScienceDirect
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial - The Lancet
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. | Semantic Scholar
Dose Dense-Intensive Chemotherapy Improves Survival in Early Stage Breast Cancer - CancerConnect
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Dose-dense chemotherapy in breast cancer and lymphoma - ScienceDirect
Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Dose-dense paclitaxel plus carboplatin <i>vs</i>. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
Real world experience with dose dense ac-paclitaxel: Two canadian cancer centers' experience | Semantic Scholar
